Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study - Wikidata - awgldk - TriplyDB

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

http://www.wikidata.org/entity/Q34753755

about

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA New combinations in the treatment of COPD: rationale for aclidinium-formoterol Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review Efficacy of tiotropium-olodaterol fixed-dose combination in COPD Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review.Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date Long-acting muscarinic antagonists.Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities.When is dual bronchodilation indicated in COPD?Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis.Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.Recent advances in the management of chronic obstructive pulmonary disease.Morning symptoms in COPD: a treatable yet often overlooked factor.Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.Prediction and prevention of exacerbations and mortality in patients with COPD.Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management.Safety of inhaled long-acting anti-muscarinic agents in COPD.Optimizing bronchodilation in the prevention of COPD exacerbations Long-acting beta2-agonists versus long-acting muscarinic antagonists in patients with stable COPD: A systematic review and meta-analysis of randomized controlled trials.Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

P2860

Q26752988-56F82186-3333-4323-A746-80F38D54352E Q26765303-88FF672B-9ABA-46E3-972B-C5B1C049F215 Q26765425-5FCBC1E3-7A8B-421E-8307-B657FE39650D Q26770504-E06AC98F-D0E5-4461-BE93-BC4E3E286BE7 Q26801661-8D15236D-4E75-44F4-A1F9-4E12907AC46F Q27015685-4728BB0C-5AC4-4233-8EA3-56E4107554E7 Q28075367-56AC9181-3203-4850-8380-62852C7B36A9 Q31165976-58792C96-5F74-47F0-95AE-335EFF3DEE56 Q33743284-7A43C216-1637-498A-B54D-F77709458E4A Q35778149-9359C272-A477-470A-AFB2-7A93D91048DD Q35937943-B2D36A9F-44D2-4762-85EC-E8AE780A0948 Q36329064-D064D087-3216-4F3C-8CBE-F282AA4BBF87 Q36356295-39976355-3388-4280-AD34-014BA9E07893 Q36929677-0668C6E6-3EF6-424F-A7AD-725531CE0680 Q37234709-75D3CF26-735C-4D7D-907D-684463B23B96 Q37468663-04FEC2AE-93B5-4A70-9F05-5D17FA6691E1 Q37494942-D3CCCA3A-D4FD-42F0-B097-5CAFFF9B4EBB Q37573177-FD9FDDC2-523B-4011-87A2-1AC57401D540 Q37603579-7F0DABA4-F006-42F0-B92F-2351131C1135 Q38371305-2A61B4A9-E375-494F-A2E8-9D92E8B970EF Q38432438-10283E64-721F-470C-8604-0C00A6478907 Q38537326-9FABF2D3-FDDA-4A12-B973-51E987CB5784 Q38586322-B7ADD8F6-77D4-4DCC-A7FB-3126C0643105 Q38604621-AA684128-7008-4D8D-A0D5-E64E71B182F7 Q38641441-1321EA6C-6F72-4A22-9858-A1B8AB057C11 Q38646619-77A9DFB0-04CC-4A3C-B43D-B57B65296F52 Q38685216-995ABA1D-B6C5-44FC-8331-28F7CC3A6A51 Q38690660-8E148038-5720-40D6-83EB-25B2D59E1046 Q38701325-B5ADA172-68F3-4037-A6B8-4BDBBEFC7EF2 Q38747579-943B17BA-DCE4-4660-8567-BB75CE350897 Q38754002-AF4DAA35-509C-4C44-B2C3-E30ADC16DE79 Q38823010-2A83A2ED-966D-4592-AC5D-2FC1646B62B1 Q39040871-D237CE11-2D5C-40AA-B4F0-8E3DB3898026 Q39232425-B280F7CC-4F8B-425D-9AEF-9FF04DC386A3 Q39386571-B35943E3-58EE-4272-9142-16149E890C94 Q39400577-A580CC2E-1E3D-49CE-A57D-53FD9D6DDE19 Q39426952-97D2BF02-DEE4-4AE7-B8D9-52506831562F Q40598255-C590E162-02DC-4CFB-A6F3-7F8FFAB772B1 Q41018618-BCBEC0CF-34F9-4BE6-8EE2-2E334E41563B Q41054096-EF8E32FF-7C4B-4B59-B9CD-C7F401C85AC1

P2860

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

http://www.wikidata.org/entity/Q34753755

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy and safety of aclidin ...... multicentre, randomised study

@ast

Efficacy and safety of aclidin ...... multicentre, randomised study

@en

Efficacy and safety of aclidin ...... multicentre, randomised study

@nl

type

label

Efficacy and safety of aclidin ...... multicentre, randomised study

@ast

Efficacy and safety of aclidin ...... multicentre, randomised study

@en

Efficacy and safety of aclidin ...... multicentre, randomised study

@nl

prefLabel

Efficacy and safety of aclidin ...... multicentre, randomised study

@ast

Efficacy and safety of aclidin ...... multicentre, randomised study

@en

Efficacy and safety of aclidin ...... multicentre, randomised study

@nl

P1433

Q34753755-CCD24300-5CFE-46B9-B3AA-F8F00FD5C209

P1476

Q34753755-8B3FE561-B603-4EC4-ADC7-9E18D0672FF0

P2093

Q34753755-16AA4C13-A94B-4DBB-8632-38330B8FB89C

Q34753755-1A1627FA-8DA0-4946-BABE-5CFCACFF1BAA

Q34753755-23CB3880-B298-4A0A-B91B-D469F4B4B249

Q34753755-58F87354-0B96-4311-8FD7-D9F233E8B755

Q34753755-643C6892-7C13-479B-84E4-DE5F3299E796

Q34753755-8FFF8344-907A-484B-BD27-171B192E5830

Q34753755-A45BEDC7-958E-458D-AC26-66AEE32A697E

Q34753755-AF653D5F-D55D-4922-A3F6-7D4E00735019

Q34753755-E1A87A9C-76AA-42BF-AA63-ECDAC574D1F5

P2860

Q34753755-205CC243-4DD7-4592-BD83-4BBD1BCCB8AD

Q34753755-21D62E26-3605-488A-9A4D-6D7EC472544A

Q34753755-51CFFB3D-826E-4B64-8855-FF43C6028D0F

Q34753755-5319E85C-35F3-49AB-8DA8-6FAAA71FF186

Q34753755-64438CB1-3640-4E4F-9876-4D35802DB117

Q34753755-6498A436-6BCE-4050-A0C3-E95DC37A72E5

Q34753755-69C6D3A2-6D32-41E4-B89E-2EDE63F423EF

Q34753755-90D965B0-CB05-4090-8601-0DAB603DB4E4

Q34753755-9438B62A-6E22-455B-905C-19A7EA24A700

Q34753755-985E84CC-3E07-483E-BE65-94DE6C3D3900

P2888

Q34753755-1B82B636-0FDF-437C-8E3B-768AD90C6FC8

P304

Q34753755-8DA55D97-FCF7-47CA-B296-AC00E7CFF069

P31

Q34753755-CC5D1743-8C4E-4C61-B147-61C80CE9C43A

P356

Q34753755-D7A0856D-9D89-4B1D-A744-9E6B4FB9C569

P478

Q34753755-7EDF22E0-0BC9-41E7-97D1-81E6ADA26F26

P577

Q34753755-4F25959B-FA43-4A3F-AC57-C351D8300C47

P5875

Q34753755-C3640A44-9277-4F3B-AED9-823FB493BBD4

P6179

Q34753755-B0B32624-E907-4A56-9B5C-07386AE1B528

P698

Q34753755-082FFFE0-136A-4DEB-9AFF-B12840813D1C

P921

Q34753755-30921A6E-A9E4-4228-8364-047966DB1559

Q34753755-C53A9A83-CE32-4408-82D7-19BCDAA84277

Q34753755-CD74EC78-8DD0-44DF-BC92-10647DF8F53B

Q34753755-F3720B87-18E4-4618-BBFC-9C4573AC921E

P932

Q34753755-AA3A487E-22CA-4018-8B52-3102D7447150

P356

1471-2466-14-178

P1433

BMC Pulmonary Medicine

P1476

Efficacy and safety of aclidin ...... multicentre, randomised study

@en

P2093

Anne Leselbaum

http://www.w3.org/2001/XMLSchema#string

Cristina Serra

http://www.w3.org/2001/XMLSchema#string

Cynthia Caracta

http://www.w3.org/2001/XMLSchema#string

Dave Singh

http://www.w3.org/2001/XMLSchema#string

Eduard Molins

http://www.w3.org/2001/XMLSchema#string

Eric D Bateman

http://www.w3.org/2001/XMLSchema#string

Esther Garcia Gil

http://www.w3.org/2001/XMLSchema#string

Paul W Jones

http://www.w3.org/2001/XMLSchema#string

Stephanie Korn

http://www.w3.org/2001/XMLSchema#string

P2860

Placebos without deception: a randomized controlled trial in irritable bowel syndrome

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

Long-acting beta2-agonists for chronic obstructive pulmonary disease

β(2) -adrenoceptor agonists: current and future direction

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial.

Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).

Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.

Minimal clinically important differences in COPD lung function.

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.

P2888

1471-2466-14-178

P304

178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2466-14-178

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268787385

http://www.w3.org/2001/XMLSchema#string

P6179

1019635583

http://www.w3.org/2001/XMLSchema#string

P698

25404569

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

multicenter trial

P932

4273456

http://www.w3.org/2001/XMLSchema#string